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Purpose: The AMP-activated protein kinase (AMPK) regulates metabolic 
homeostasis and plays a protective role in the ischemic and diabetic hearts. 
The A-769662 compound, which directly binds and activates AMPK, has 
recently been characterized. Here, we studied the impact of A-769662 on car-
diac AMPK signaling and glucose uptake which is known to participate in the 
protective action of AMPK.
Methods: Insulin and/or A-769662 were used to stimulate adult cardio-
myocytes. The effect of A-769662 on the action of other AMPK activators has 
been also tested. Glucose uptake was measured by the detritriation rate of 
[2-3H] glucose. The phosphorylation state of signaling elements was measured 
by immunoblot. AMPK activity was assessed by the incorporation of radio-
active phosphates on a specific synthetic peptide. Cell death and ROS produc-
tion were evaluated using propidium iodide or by monitoring oxidation of a 
fluorescent probe, respectively.
Results: Glucose uptake was increased by both insulin and oligomycin. In 
the presence of insulin, oligomycin leads to an overstimulation of glucose 
uptake that correlated with an Akt overphopsphorylation. In contrast, A-
769662 had no insulin sensitizing effects. Indeed, A-769662 promoted AMPK 
phosphorylation but did not stimulate glucose uptake and did not induce an 
overphosphorylation of Akt or an overstimulation of glucose uptake in the 
presence of insulin. Otherwise, A-769662 potentiates the effects of other 
AMPK activators. We showed an overphosphorylation of AMPK and of its 
substrate ACC, when A-769662 was added to oligomycin or hypoxia. This 
potentiation effect was accompanied by an overstimulation of glucose uptake 
and by a decrease in cell mortality and ROS production.
Conclusions: A-769662, by itself, is unable to stimulate glucose uptake or 
to increase insulin sensitivity. However, its ability of potentiating the action 
on other AMPK activators makes it a potentially useful participant in the pro-
tective role of AMPK in the heart.
0309
A-769662, a specific AMP-activated protein kinase (AMPK) activator, 
prevents cardiomyocyte hypertrophy independently of the already 
identified AMPK downstream targets
Florence Mailleux (1), Roselle Gélinas (1), Bénédicte Demeulder (1), 
Johanna Hammond (2), Audrey Ginion (1), Louis Hue (1), Jean-Luc 
Balligand (2), Jean-Louis Vanoverschelde (1), Christophe Beauloye (1), 
Sandrine Horman (1), Luc Bertrand (1)
(1) Université Catholique de Louvain, Recherche cardiovasculaire, 
Woluwe-Saint-Lambert, Belgique – (2) Pôle de pharmacologie et théra-
peutique, Bruxelles, Belgique
Background: AMPK activators, like resveratrol or metformin, inhibit 
pathological cardiac hypertrophy. However, despite evidence for their anti-
hypertrophic effect, it seems that this phenomenon is mainly circumstantial. 
Indeed, those agents induce a rather non-specific AMPK activation by 
increasing the AMP/ATP ratio or by mimicking AMP. Hence, the aim of this 
study was to test the ability of a more specific AMPK activator, called A-
769662, to prevent phenylephrine (PE)-induced hypertrophy in cultured neo-
natal rat ventricular myocytes (NRVM) and in adult rat ventricular myocytes 
(ARVM).
Method: Alpha-actinin immunostaining, radio labelled amino acid incor-
poration, nuclear factor of activated T-cells (NFAT) activity, hypertrophy-
linked gene expression and protein phosphorylation were analysed to deter-
mine NRVM hypertrophy. Cell surface area and protein phosphorylation were 
analysed to define ARVM hypertrophy.
Results: Using dose–response experiments and genetic AMPK silencing, 
we show here that A-769662 is able to prevent the development of PE-induced 
NRVM hypertrophy by an AMPK-dependant mechanism. This hypertrophy 
prevention correlates with the modification of AMPK-related key regulators of 
cardiac hypertrophy including ~50% lower protein synthesis (p<0.05) and a 3-
fold decreased phosphorylation of p70S6K (p<0.05) but also a significant 
decrease in ERK1/2 (~50%, p<0.05) and NFAT signalling (~90%, p<0.05) 
when high concentrations of A-769662 were used in combination with PE vs
PE alone. However, while low dose of A-769662 (12.5 μM) still efficiently 
prevents PE-induced NRVM hypertrophy (p<0.05) none of the known AMPK 
downstream targets are modified at this dose, showing a discrepancy between 
hypertrophy prevention and known AMPK target regulation. The same dis-
crepancy was observed in ARVM at low dose of A-769662.
Conclusion: Collectively, our results using low dose of A-769662 suggest 
a yet to be identified mechanism by which AMPK can regulate cardiac hyper-
trophy.
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AMPK is activated during platelet aggregation and controls the phospho-
rylation state of key cytoskeletal targets. CaMKKβ is responsible for 
thrombin-induced AMPK activation. Substantial differences have been 
observed between human and murine platelets. This study aims to bring out 
the differences in AMPK signalling pathway between human and murine 
platelets. Only α1 catalytic subunit of AMPK is present in human platelets. 
Thrombin induces a dramatic AMPKα1 activation and subsequent acetyl-CoA 
carboxylase (ACC) phosphorylation, while thromboxane A2 (U46619) and 
collagen exert a marginal effect on both enzymes. ADP has no effect at all. 
These differences cannot be entirely related to a lower calcium production in 
response to U46619, collagen and ADP. Indeed, U46619 increases calcium 
with a similar extent than thrombin while it does not modify ACC phosphor-
ylation. PAR1 but not PAR4-activating peptide reproduces the effect of 
thrombin on ACC. In addition, inhibition of CaMKKβ/AMPKα1 activation 
blunts platelet aggregation in response to thrombin and does not affect the 
response upon stimulation by the other agonists.
Murine platelets express AMPKα1 and AMPKα2. AMPK can be activated 
either by thrombin or U46619 or collagen but not by ADP. The absence of 
AMPKα1 blocks ACC phosphorylation induced by the three agonists. It 
mainly inhibits the thrombin-induced platelet aggregation but also signifi-
cantly reduces aggregation in response to U46619 and collagen. The absence 
of AMPKα2 does not affect the increase in ACC phosphorylation, whatever 
the agonist used.
Conclusions: AMPKα1 is the sole catalytic subunit of AMPK expressed 
in human platelets and is activated by thrombin through PAR1. Murine plate-
lets contain both catalytic subunits although α1 plays a predominant role. In 
mice, thrombin is not the predominant AMPK activator probably because of 
the difference in the type of PAR expression. Signalling events of mouse 
platelets can diverge from those of human platelets.
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